The World Health Organization has tracked a new COVID-19 variant that has emerged across multiple region. Amid this, the Food and Drug Administration has approved a COVID-19 vaccine from Moderna that ...

Paradromics, a competitor of Neuralink, announced Monday it safely implanted a brain-computer interface into a human patient ...

Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID ...

"Our study findings confirm that healthy dietary patterns in mid to late life and their improvement over time may prevent ...

The approval of the mNEXSPIKE vaccine comes less than a week after Health and Human Services Secretary, Robert F. Kennedy Jr. announced the COVID vaccine for healthy children and healthy pregnant ...

Moderna’s newest lower-dose COVID-19 vaccine is approved for all adults 65 and older, and for people aged 12 to 64 who are at ...

The FDA approved a new Moderna COVID-19 vaccine for adults 65 and older. "We were told that pain was temporary. As it turns ...

The new mRNA vaccine encodes the receptor-binding domain and the N-terminal domain of the SARS-CoV-2 spike protein ...

From eligibility to dosage and future rollout, here’s what you need to know about the FDA’s latest vaccine approval.

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.

Shares of Moderna climbed Monday after the Food and Drug Administration approved a new COVID-19 vaccine from the drugmaker.

FDA approves Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk groups Phase 3 trial shows mNEXSPIKE outperforms original ...